Our approach

CERo’s novel approach to fighting cancer harnesses the power of the body’s innate and adaptive immune systems.

We are pioneering a new generation of autologous T-cell-based therapies that uniquely combine attributes of macrophages and dendritic cells of the innate immune system with those of T cells (adaptive immune system) for treatment of both hematologic and solid tumor cancers, and potentially other disease areas. This integrated approach draws on recent advances in synthetic and T cell biology with the intent to increase the curative potential and safety profile of current therapies.

Multifunctional T cells with enhanced anti-tumor capabilities

Our core technology is based on a new class of engineered cells called chimeric engulfment receptors (CERs), which integrate multiple features of both the innate (engulfment and antigen presentation) and adaptive (T-cell activation) immune systems. Introduction of a CER into a T cell allows tumor recognition via a stress ligand, triggering capture of tumor cell fragments by the CER T cell. T-cell signaling domains of the CER then mediate activation of T-cell cytotoxicity directly against the tumor. An additional component of the CER enables the T-cell to process and present tumor associated antigen and stimulate a broad secondary immune response. Thus, CER T cells have the unique potential to recognize a variety of tumors and to amplify the body’s immune response against the tumor.

Investors and Partners